Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins
Silvie Rimpelová,
Michal Kolář,
Hynek Strnad,
Tomáš Ruml,
Libor Vítek,
Helena Gbelcová
Affiliations
Silvie Rimpelová
Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague, Czech Republic
Michal Kolář
Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
Hynek Strnad
Laboratory of Genomics and Bioinformatics, Institute of Molecular Genetics, Czech Academy of Sciences, Vídeňská 1083, 142 20 Prague, Czech Republic
Tomáš Ruml
Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague, Czech Republic
Libor Vítek
Institute of Medical Biochemistry and Laboratory Diagnostics, and 4th Department of Internal Medicine, 1st Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic
Helena Gbelcová
Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University, Špitálska 24, 813 72 Bratislava, Slovakia
Statins have been widely used for the treatment of hypercholesterolemia due to their ability to inhibit HMG-CoA reductase, the rate-limiting enzyme of de novo cholesterol synthesis, via the so-called mevalonate pathway. However, their inhibitory action also causes depletion of downstream intermediates of the pathway, resulting in the pleiotropic effects of statins, including the beneficial impact in the treatment of cancer. In our study, we compared the effect of all eight existing statins on the expression of genes, the products of which are implicated in cancer inhibition and suggested the molecular mechanisms of their action in epigenetic and posttranslational regulation, and in cell-cycle arrest, death, migration, or invasion of the cancer cells.
